Literature DB >> 1664187

C5a structural requirements for neutrophil receptor interaction.

K W Mollison1, T A Fey, R A Krause, L Miller, R P Edalji, R G Conway, W Mandecki, M A Shallcross, M Kawai, Y S Or.   

Abstract

A number of C5a modifications were tested to determine effects on receptor binding to polymorphonuclear leukocyte (PMNL) membrane receptors and triggering of PMNL chemokinesis and myeloperoxidase (MPO) release. Site-directed mutagenesis was used to probe relationships of key C-terminal residues, and suggested a role for additional sites, particularly Lys19-20. A synthetic peptide based on C5a 19-30, weakly inhibited C5a binding. Potency of the C-terminal octapeptide, a full agonist, was markedly improved by a single Phe substitution for His67, and a Phe point mutation at this site was shown to enhance activity of the full recombinant protein.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1664187

Source DB:  PubMed          Journal:  Agents Actions Suppl        ISSN: 0379-0363


  5 in total

1.  Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding.

Authors:  X Zhang; W Boyar; N Galakatos; N C Gonnella
Journal:  Protein Sci       Date:  1997-01       Impact factor: 6.725

2.  Antagonistic peptides against human anaphylatoxin C5a.

Authors:  Y Kaneko; N Okada; L Baranyi; T Azuma; H Okada
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

3.  The pharmacophore of the human C5a anaphylatoxin.

Authors:  M J Toth; L Huwyler; W C Boyar; A F Braunwalder; D Yarwood; J Hadala; W O Haston; M A Sills; B Seligmann; N Galakatos
Journal:  Protein Sci       Date:  1994-08       Impact factor: 6.725

4.  A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.

Authors:  W Bautsch; T Kretzschmar; T Stühmer; A Kola; M Emde; J Köhl; A Klos; D Bitter-Suermann
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

5.  Expression and subcellular targeting of human complement factor C5a in Nicotiana species.

Authors:  Henrik Nausch; Heike Mikschofsky; Heike Mischofsky; Roswitha Koslowski; Udo Meyer; Inge Broer; Jana Huckauf
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.